Background: Glutathione S-transferase (GST) enzymes are critical for detoxifying reactive oxygen species (ROS) and their products which have been implicated in the pathology of inflammatory diseases such as atopic dermatitis (AD).
Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic and eczematous skin lesions in distinct locations. The onset of AD usually occurs in early childhood, with ;80% of cases having *Corresponding author: Jayong Chung, PhD, Department of Food and Nutrition Kyung Hee University, Hoegi-dong 1, Dongdaemun-gu, Seoul 130-701, Korea Phone: q82-2-961-0977, fax: q82-2-968-0260, E-mail: jchung@khu.ac.kr Received April 5, 2009 ; accepted August 5, 2009 ; previously published online October 21, 2009 clinical symptoms by 5 years of age (1) . AD is the most common allergic childhood disease, affecting up to 20% of children worldwide (2) .
While the pathology of AD is very complex and not fully understood, it is widely accepted that both genetic and environmental factors contribute to the development of AD. The genetic contribution seems to be particularly strong; results from twin studies show that disease concordance rates are much higher in monozygotic (72%-86%) compared with dizygotic twins (21%-23%) (3) . In addition, recent studies have found significant associations between AD and polymorphisms in genes such as IL4, IL13, IL4R, CMA1, and SPINK5 (4) . These data suggest that multiple genetic factors contribute to the development of AD.
Inflammation is a critical feature of AD and is often associated with increased production of reactive oxygen species (ROS). These can cause oxidative damage to cellular components such as DNA, lipids and proteins. In skin inflammation associated with AD, ROS are released during the activation and infiltration of lymphocytes, monocytes, and eosinophils (5-7). In addition, markers of oxidative stress have been shown to be increased in children with AD (8) , implicating ROS and their products in the pathology of AD. Thus, it is possible that genetic factors that affect the capacity of cells to detoxify ROS and their products are important determinants in the development of AD.
Glutathione S-transferases (GSTs) belong to a multigene family of phase II detoxification enzymes and protect cells against oxidative damage. GST detoxifies ROS and their products by catalyzing conjugation with reduced glutathione (GSH) prior to excretion from the body (9) . Several genetic polymorphisms have been identified in GSTP1, GSTM1, and GSTT1 isozymes. A single nucleotide substitution (A-G), resulting in an Ile to Val change at residue 105, has been associated with altered heat stability and substrate preference of GSTP1 (10) . Similarly, homozygous deletion of the GSTM1 and GSTT1 genes leads to the absence of the GSTM1 and GSTT1 proteins and their activity resulting in a null phenotype (11) . Previous studies have reported an association between GST polymorphisms and an increased risk of inflammatory diseases such as asthma (12) (13) (14) (15) (16) and rheumatoid arthritis (17) . A limited number of studies have examined the association of GST polymorphisms with risk of AD; the findings have been inconclusive (18) (19) (20) . The purpose of this study was to investigate the relationship of polymorphisms in GSTM1, GSTT1, and GSTP1 with the risk of AD in preschool age children. In addition, biomarkers of oxidative stress were analyzed with respect to GST polymorphisms in children with AD and healthy children.
Materials and methods

Subjects
To investigate the association between various selected factors and childhood AD, we conducted a cross-sectional, population-based study using a convenience sample of children, 2-6 years old, from 18 preschools located in two metropolitan cities (Seoul and Incheon) of Korea. Of the 1571 children who participated in the cross-sectional study, 765 were recruited for the genetic case-control study. Of these, we selected AD cases and controls based on responses to questions in the Korean version of the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire (21) . AD was considered to be present if the children's parents replied positively to the following questions: ''Has your child ever had an itchy rash (also called atopic dermatitis), which was coming and going for at least 6 months?'' and, ''Has your child had this itchy rash at any time in the last 12 months?''. The children whose parents provided negative responses to both questions and who had not taken any medication due to AD were assigned as control subjects. All of the study subjects were Korean. Information concerning basic demography and history of family atopic diseases was also collected from the questionnaire. The severity of AD was evaluated by a pediatrician using the Scoring Atopic Dermatitis (SCORAD) index. All participants provided written informed consent for study participation. The study protocol was approved by the Ethics Committee of the College of Human Ecology at Kyung Hee University.
Genotyping
Genomic DNA was extracted from buffy coats using the AxyPrepீ Blood Genomic DNA miniprep kit (Axygen biosciences, Union City, CA, USA). Polymorphism in GSTP1 Ile105Val was identified using the PCR-restriction fragment length polymorphism (RFLP) method, as described previously (22) . Briefly, 50 ng genomic of DNA was used as template in a PCR reaction with the HotStarீ DNA polymerase kit (Qiagen, Valencia, CA, USA) and an MJ mini gradient thermal cycler (Bio-Rad, Hercules, CA, USA). PCR conditions were initial denaturation at 958C for 5 min, followed by 35 cycles of 558C for 30 s, 728C for 30 s, and 958C for 30 s, and a final extension at 728C for 5 min. PCR products (176 bp) were digested with 2.5 units Alw26I (New England Biolabs, Ipswich, MA, USA), separated on a 3.5% agarose gel and stained with ethidium bromide. Bands were detected using the Gel Doc XR system (Bio-Rad, USA). The presence of the GSTP1 Val105 allele was identified by detection of cleaved PCR products (91 bp and 85 bp) following digestion. A multiplex PCR method was used to detect GSTT1 and GSTM1 polymorphisms, with the b-globin gene used as internal standard. Briefly, GSTM1, GSTT1, and b-globin genes were amplified simultaneously amplified by PCR using mixed primers for each gene, as described by Wilson et al. (23) . PCR conditions were initial denaturation at 948C for 3 min, followed by 27 cycles of 948C for 30 s, 628C for 30 s, and 728C for 45 s, and a final extension step of 10 min at 728C. Following amplification, the PCR products were analyzed on a 2% agarose gel and stained with ethidium bromide. The presence or absence of the GSTT1 (480 bp) and GSTM1 (215 bp) genes was determined in the presence of the control b-globin gene (268 bp).
Serum total antioxidant capacity (TAC)
Serum TAC was measured using a commercially available kit (Antioxidant Assay kit, Cayman chemical, Ann Arbor, MI, USA) following the manufacturer's instructions. The assay is based on the ability of antioxidants to inhibit the oxidation of ABTS w2,29-Azino-di-(3-ethylbenzthiazoline sulfonate)x to ABTS
•q by metmyoglobin (24) . The amount of ABTS •q produced was monitored spectrophotometrically at 750 nm. TAC of serum was compared with that of Trolox, a watersoluble tocopherol analogue, and quantified as the mM Trolox equivalent.
Erythrocyte total GSH
Erythrocyte total GSH concentrations were determined as described by Rahman et al. (25) . Briefly, erythrocyte pellets were resuspended in four volumes 5% meta-phosphoric acid (MPA) to prevent oxidation of GSH. Following centrifugation at 3000=g at 48C for 10 min, the clear supernatants were collected and mixed with Ellman's reagent wDTNB (5,59-dithio-bis(2-nitrobenzoic acid))x and GSH reductase in the dark. After incubation at room temperature for 30 s, the reactions were initiated by the addition of b-NADPH. The rate of formation of TNB at 412 nm during the first 2 min was proportional to total GSH concentration. Values for total GSH were calculated from a standard curve and expressed as mmol/g Hb.
Plasma malondialdehyde (MDA)
Plasma MDA was measured using a commercially available kit (Bioxytech ᮋ MDA-586ீ, Oxis International, Inc, Foster City, CA, USA). This colorimetric assay uses N-methyl-2-phenylindole (NMPI) as chromogen. It reacts specifically with MDA, but not with other lipid peroxidation products such as 4-hydroxyalkenals. Plasma MDA concentrations were derived by calculating the third derivative spectrum of the absorption spectrum (400-700 nm) for each sample, according to the manufacturer's recommendations. Third derivative spectroscopy helps eliminate or reduce the effects of baseline drift and interference from other biologic compounds in the sample.
Statistical analyses
All data were analyzed using SAS for Windows 9.1 (SAS Institute Inc., Cary, NC, USA) and SigmaPlot 10.0 (Systat Software Inc., San Jose, CA, USA). To test differences between children with AD and healthy controls, Student's ttest or the x 2 -test was used, as appropriate. For the association between GST genotypes and risk of AD, logistic regression analysis was performed to calculate the odds ratio (OR) and 95% confidence intervals (CI), after controlling for gender and age.
Results
Associations between GST polymorphisms and AD susceptibility were studied in 124 unrelated children with AD and 260 healthy children. Table 1 summarizes the characteristics of study participants. Compared to controls, the group with AD had significantly higher concentrations of serum total IgE and blood eosinophil counts, typical characteristics of AD. In addition, the proportion of children with a parental history of allergic diseases was significantly higher among children with AD compared with controls. Age, body mass index (BMI), and the proportion of males were not different between the two groups. The severity of AD as evaluated by the SCORAD index showed that most children with AD (80%) in the study suffered from mild disease (data not shown). Table 2 summarizes the distribution of GSTM1, GSTT1, and GSTP1 genotypes among children with AD and controls. In children with AD, the frequencies of GSTM1 null and GSTT1 null were 58.1% and 55.6%, respectively. Similarly, more than half of the controls had null genotypes for GSTM1 and GSTT1, 56.5% and 50.4%, respectively. Overall, no significant association was found between GSTM1 or GSTT1 null genotypes and the risk of AD in children. In contrast, the distribution of the GSTP1 Ile105Val allele was significantly different between children with AD and controls. Carriers of the GSTP1 Val105 allele (Ile/Val or Val/Val) were more frequent among children with AD compared with controls (37.9% and 27.3%, respectively). Using logistic regression analyses with adjustments for gender and age, children with the GSTP1 Val105 allele had a 1.6-fold increased risk of developing AD compared to GSTP1 Ile/Ile homozygotes (95% CI 1.03-2.56) ( Table 2 ). However, this association was not statistically significant after Bonferroni correction for multiple testing. The distribution of GSTP1 Ile/Ile, Ile/Val, and Val/Val genotypes in controls was 72.7%, 25%, and 2.3%, respectively. The frequency of the Val105 allele was 14.8%.
We also investigated the risk of AD associated with combinations of two GST genotypes. The combination of the GSTP1 Val105 allele and GSTT1 null genotype increased the AD risk by up to 2.3-fold (95% CI 1.19-4.41) compared to GSTP Ile/Ile homozygotes and children with GSTT1 genotypes (Table 3) . However, the significance of the association was lost after Bonferroni correction. The combination of the GSTP1 Val105 allele and the GSTM1 null also appeared to increase the risk of AD (ORs1.73, 95% CI 0.93-3.21), although this increase was not statistically significant (ps0.09). There was no significant increase in AD risk with respect to GSTM1 and GSTT1 genotypes.
To investigate if the degree of oxidative stress was associated with AD, we compared blood concentrations of GSH, TAC, and MDA between children with AD and controls ( Figure 1 ). Mean serum TAC was significantly lower in children with AD (1.70 mM trolox eq.) compared with controls (1.43 mM trolox eq.) (p-0.001). However, mean plasma concentrations of MDA were higher, although not significantly, in children with AD compared with controls (686.9 nM vs. 593 nM, respectively, ps0.12) (Figure 1) .
To further explore the mechanisms that could explain the association of the GSTP1 polymorphism with increased risk of developing AD we analyzed the above biomarkers with respect to the GSTP1 Ile105Val genotype. GSTP1 Ile/Ile homozygotes had significantly higher concentrations of GSH compared with Val105 allele carriers (10.8 mmol/g Hb vs. 10.1 mmol/g Hb, respectively, ps0.03) ( Table 4) .
When we stratified the subjects into two groups (children with AD and controls), the association of the GSTP1 genotype with erythrocyte GSH concentrations in each group was consistent with data derived from all subjects, but this was not statistically significant (Table 4) . No significant differences were found in TAC or MDA with respect to GSTP1 genotype in children with AD or healthy controls.
Discussion
GST enzymes are critical for the detoxification of ROS and their products, which have been implicated in the pathology of inflammatory diseases such as AD. We reasoned that genetic polymorphisms of GST enzymes, which alter cellular protection against oxidative damage, may contribute to the risk of development of AD. We examined the association of GSTP1, GSTM1, and GSTT1 gene polymorphisms with the risk of AD in preschool age children. The Val105 allele of GSTP1 was significantly associated with a higher risk of AD. In addition, children with a particular combination of variant genotypes (GSTP1 Val105 and GSTT1 null) had an even greater risk (2.3-fold increase) of AD, compared to children with GSTP1 Ile/Ile and GSTT1 present genotypes. GST gene polymorphisms have been associated with the risk of various skin diseases. For example, the GSTP1 Val105 allele has been shown to increase the incidence of arsenic-related skin lesions (26, 27) . This is consistent with our observations that GSTP1 Val105 allele carriers had an increased risk of developing AD. However, many reports have shown that the Val105 allele is associated with a decreased risk of allergic asthma (12, 13) , although some studies reported that the Val105 allele actually increased the risk of asthma (14, 16) . The GSTP1 Ile105Val polymorphism was not significantly associated with aspirin-intolerant asthma in Koreans (28) . There are several possible explanations for the discrepancies between these studies and our findings. First, the pathogenesis of asthma and AD may be quite different. Asthma involves changes in lung function while AD is a type of skin disease. Thus, comparison of data from asthma patients with AD may not be appropriate. Second, the frequencies of the Val105 allele in Asians are much lower than those of other ethnicities, which may explain the conflicting findings. For example, the Val105 allele decreased the risk of asthma in Northern Europeans for which the Val allele frequency is 47.7% (12) , whereas the Val105 allele increased the risk of asthma in the Japanese population for which the Val allele frequency is 13.4% (14) . Studies in Taiwanese individuals (Val allele frequencys25.3%) (15) have shown that the Ile105 homozygosity was related to an increased risk only in areas with high air pollution, and no association was found in areas with low air pollution. These data suggest that the role of GSTP Ile105Val polymorphisms in the risk of AD could differ depending on ethnicity. The frequency of the Val105 allele in our study was 14.8%, which is very close to that of the Japanese population. Finally, other factors such as the subjects age and environmental factors may also cause differences.
Unlike the GSTP1 Ile105Val polymorphism, neither GSTM1 nor GSTT1 present/null polymorphisms alone had a significant effect on risk of AD. In contrast, we found that carriers of two variant genotypes (GSTP1 Val105 and GSTT1 null) were at higher risk of AD than carriers of a single variant GSTP1 or GSTT1 genotype, or carriers of no variant genotypes. Also, the combined effect of the GSTP1 and GSTM1 variant genotypes on the risk of AD tended to be higher than the effect of GSTP1 or GSTM1 variants alone. Similar to our findings, several studies have indicated that the influences of GST genotypes on disease risk become more significant with an increase in the number of GST variant alleles (29) (30) (31) . This is likely due to GST enzymes having similar substrate specificities. While the absence or defect of a single GST enzyme has negligible effect on the risk of disease, possibly due to compensation by other GSTs, defects in multiple GST enzymes may contribute to significant alterations in cellular protection against oxidative stress and increase susceptibility to disease.
Earlier studies have reported that oxidative stress is associated with the development and severity of AD. Urine concentrations of 8-hydroxy-29-deoxyguanosine (8-OHdG, a marker of oxidative DNA damage) are significantly higher in children with AD compared with healthy controls (8) . Also, urinary acrolein-lysine adducts (markers of lipid peroxidation) are significantly higher in children with AD (32) . Our data showed that TAC was significantly decreased, but plasma MDA (products of lipid peroxidation) tended to be increased in children with AD compared to healthy controls. This supports the association of oxidative stress and altered antioxidant status with development of AD. The relatively small difference in plasma MDA and erythrocyte GSH between the two groups may be due to the fact that most of the children with AD that participated in our study had a mild case of the disease. Niwa et al. (33) have shown that the concentrations of carbonyl moieties (markers of oxidative protein damage) are increased in skin biopsies from patients with AD, and are directly correlated with disease severity.
We found that GSTP1 Val105 allele carriers had significantly lower GSH concentrations compared to GSTP1 Ile/Ile homozygotes. Although the difference in GSH concentrations between genotypes is relatively small and may not be clinically significant, this observation suggests a potential mechanism for how the GSTP1 Ile105Val polymorphism increases the risk of AD. Since GSH is an important component that acts to scavenge ROS and regenerate other antioxidants, GSH depletion may represent increased oxidative stress in GSTP1 Val105 allele carriers. Similar to our findings, Ercan et al. (34) reported that asthma patients with homozygous GSTP1 Val105 genotypes have lower GSH concentrations compared to patients with other genotypes. The Ile to Val substitution at position 105 results in steric restriction of the putative binding site (H-site) due to shifts in the side chains of several amino acids. This steric hinderance may alter the substrate specificity and catalytic activity of GSTP1. In vitro studies have shown that the Val105 variant is more active with diol epoxides of polycyclic aromatic hydrocarbons (35) , but less active than the Ile105 enzyme with various other substrates, including 1-chloro-2,4-dinitrobenzene (36) . Further, the thermal stability of the Val105 enzyme is reported to be significantly lower than that of the Ile105 enzyme (37) . More importantly, erythrocytes from individuals with the Val105 allele displayed significantly decreased GST activity compared with that seen in Ile/Ile homozygotes (38) . Together, these characteristics may be responsible for the increased oxidative stress of GSTP1 Val105 carriers and for the increased susceptibility to AD.
It is interesting to note that serum TAC was much lower in children with AD compared with healthy controls. However, no significant differences were found with respect to GSTP1 genotype. This suggests that low TAC could be an independent risk factor for AD, in addition to GSTP1 genotype. Serum TAC measurements represent the combined activities of all antioxidants present in serum, including dietary antioxidant vitamins such as ascorbic acid, a-tocopherol, and b-carotene (24) . The imbalance of ROS production and antioxidants can lead to increased oxidative stress. Thus, it is possible that in addition to increased ROS production, low TAC in children with AD may be due to low intake of dietary antioxidants, implicating dietary antioxidant intake with AD risk. Several previous studies have reported the beneficial association of dietary antioxidant vitamins with the risk of atopic diseases (39) (40) (41) . For example, a higher concentration of vitamin C in breast milk is associated with a reduced risk of AD in infants (ORs0.30, 95% CI 0.09-0.94) (42) . Further studies to identify potential interactions between dietary antioxidant intake and GSTP1 genotype in the risk of AD are needed.
In conclusion, our results suggest that the GSTP1 Val105 allele is an important determinant for susceptibility to AD in preschool age children. These findings suggest a role for increased oxidative stress and altered antioxidant status in the pathogenesis of the disease. This study is limited by the small number of subjects and the associations of the GST polymorphisms with AD risk become suggestive after Bonferroni correction. Further studies with larger sample sizes are needed to confirm and substantiate the present findings.
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